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The malnutrition caused by liver cirrhosis (LC) often worsens the course of the disease. Patients affected by LC often have a low bioavail-
ability of the anabolic liver peptide insulin-like growth factor (IGF)-I. The present study was undertaken to investigate the effect of low
doses of IGF-I on the nutritional status and in vivo jejunal transport of D-galactose in anatomically, pathologically and biochemically con-
firmed moderate, non-ascitic, cirrhotic rats. LC was experimentally induced in growing rats by inhalation of CCl4 and addition of pheno-
barbital to drinking water. Both the nutritional status, as evaluated by N balance, and in vivo intestinal transport of D-galactose, were
significantly impaired in cirrhotic rats. As compared with healthy rats, administration of 20mg human recombinant IGF-I/kg body
weight for 14 d to cirrhotic rats significantly improved N balance variables and restored in vivo intestinal transport of the sugar. However,
IGF-I had no effect on the steatorrhoea associated with LC. These results suggest that low doses of IGF-I may have beneficial effects on
the malnutrition associated with moderate LC.
Cirrhosis: Insulin-like growth factor-I: Nitrogen balance: Intestinal absorption
It is well documented that patients affected by liver cirrho-
sis (LC) often have malnutrition, which further exacerbates
liver disease (McCullough & Tavill, 1991; Mun˜oz, 1991;
Merli et al. 1992).The ascitis associated with advanced
LC, mainly due to reduced hepatic albumin synthesis as
well as to portal hypertension, resembles that of protein
malnutrition (kwashiorkor) (Cabre & Gassull, 1999).
Moreover, patients with LC may have reduced concen-
trations of lecithins and bile salts, and thus reduced ability
to absorb lipids (Greco et al. 1998). As a consequence, the
nutritional and metabolic disturbances associated with mal-
nutrition trigger some of the pathophysiological events
linked to LC (Mezey, 1978) and increases morbidity in
patients with LC (O’Keefe et al. 1980; Abad et al. 1987;
McCullough, 1992), but the physiological events related
to nutritional status in patients with LC are poorly under-
stood (Kondrup et al. 1992).
On the other hand, plasma levels and bioavailability of
insulin-like growth factor (IGF)-I, an anabolic peptide syn-
thesized mainly in the liver upon the active stimulation by
somatotropin, are reduced in patients with LC (Schimpff
et al. 1977; Hattori et al. 1992; Moller et al. 1993;
Donaghy et al. 1995). It is well known that growth hor-
mone activates Jak2, which leads to stimulation of
growth, a specific effect mediated mainly by stimulation
of IGF-I transcription. In addition, ligand binding to the
growth hormone receptor is known to have insulin-like
metabolic effects (Butler et al. 2002). There is a strong
negative correlation between the degree of LC and
plasma concentrations of IGF-I (Donaghy et al. 1995;
Moller et al. 1995). The lower IGF-I plasma levels, the
higher the severity of the hepatopathy (Scholmerich et al.
1987; Canfriez et al. 1991; Donaghy et al. 1995). It has
been shown that IGF-I bioavailability depends not only
upon plasma levels of the free peptide, but also on its affi-
nity to plasma binding proteins, especially binding protein-
3 (Imai et al. 2000). While hepatocytes have a reduced
IGF-I receptor population, enterocytes express them abun-
dantly (Corkins et al. 1999; MacDonald, 1999) and there-
fore plasma free IGF-I levels may influence intestinal
physiology and be involved in the malnutrition related to
LC through impairment of nutrient absorption.
In addition, the nutritional status influences the
expression of both IGF-I and IGF-I-binding protein
(Bang & Hall, 1992), with reduced levels of plasma
IGF-I found in undernourished animals and human subjects
(Holt et al. 1998). These levels are commonly used as sen-
sitive markers of nutritional status (Imai et al. 2000). Very
recently, some authors (Carro et al. 2002) have shown that
IGF-I is a physiological regulator of brain amyloid levels.
We recently showed that in intestinal brush border mem-
brane vesicles, the reduced transport of galactose and amino
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acids shown by LC rats was corrected by IGF-I adminis-
tration (Castilla et al. 1997b; Pascual et al. 2000). Since
IGF-I levels correlate well with the degree of LC and nutri-
tional status, the aim of the present study was to further
investigate whether the administration of the anabolic
peptide to cirrhotic rats was capable of improving N balance
and nutritional performance of laboratory animals.
Materials and methods
Animals and experimental design
All the experimental procedures were performed in accord-
ance with The Guiding Principles for Research Involving
Animals (National Academy of Sciences, 1991). Male
Wistar rats (n 60), body weight (BW) approximately
160–170 g, were housed in suspended plastic-bottomed
mesh cages (four or five animals per cage) in an air-con-
ditioned room at 22^28C on a 12 h light–dark cycle
(lights on at 06.00 hours). Animals were fed a standard
commercial diet (Purina diet; Purina, Valladolid, Spain).
LC was induced by CCl4 (Merck, Madrid, Spain) inhala-
tion. The organic solvent was administered two times per
week, with a progressively increasing exposure time (ran-
ging from 1 to 5 min) during the 11 weeks. To accelerate
development of LC, phenobarbital (Phen) (Luminalw;
Bayer, Leverkusen, Germany) was added to the drinking
water (400 mg/l) throughout the entire period of cirrhosis
induction, beginning 1 week before the first CCl4 exposure
(Chatamra & Proctor, 1981; Ariosto et al. 1989).
The study protocol was approved by the Committee of
Animal Care of the Centro de Investigacı`ou´ de Farmacolo-
gı´c Aplicada (CIFA) of the University of Navarra and was
carried out in accordance with the Guide for the Care and
Use of Laboratory Animals.
Beginning on day 0 of the experimental period, two
groups of CCl4-induced cirrhotic rats received either
saline (9 g NaCl/l; group CI) or subcutaneous human
recombinant IGF-I (20mg/kg BW per d; group CI þ IGF-
I) for 2 weeks. Three other groups of healthy rats (n 12
per group) were used as control animals; one group
received saline (9 g NaCl/l) during the last 2 weeks of
the study (group CO). The other two groups were set up
to further explore the effect of IGF-I and Phen on healthy
rats: one received IGF-I (20mg/kg BW per d; CO þ IGF-
I), and the other only Phen throughout the entire exper-
imental period (CO þ Phen). Excluding the cirrhosis
induction, these three CO groups were subjected to the
same protocol as CI rats.
At the beginning and the end of the experiment, blood
(about 3 ml) was collected from the retroocular plexus in
all rats for biochemical and hormonal determinations.
After 14 d of peptide administration and without interrupting
IGF-I injections, seven rats per group were housed in metab-
olism cages (Tecniplast 3701MO-000; Panlab, Barcelona,
Spain) for 6 d so that food, urine and faeces could be col-
lected in order to carry out the N balance study (Maxvold
et al. 2000). Determination of total fat (total diethyl ether
extract) in faeces was carried out (Longwell & Stiles,
1968) as an indirect approach to assess intestinal lipid
absorption. Once the metabolic study was over, lightly
anaesthetized rats were killed by decapitation. The
jejunum, liver, testicles, several muscles, femur and spleen
were carefully dissected out and weighed. Liver samples
were processed for histological examination and sections
of jejunum were taken for functional and histological
studies.
In vivo intestinal absorption of D-galactose
The in vivo absorption of D-galactose by jejunal loops was
assessed by the validated method of Ponz et al. (1979).
Once the metabolic study period was over, animals (n 5)
were fasted overnight with free access to water. Rats
were anaesthetized with subcutaneous injections of
sodium thiopental (40 mg/kg BW). A 200 mm mid-jejunum
loop was hooked between two glass cannulas and con-
nected to a perfusion system via a constant flow electric
pump (Microperpex model 2123; LKB, Stockholm,
Sweden). The jejunal loop was replaced in the abdomen
and rinsed free of intestinal contents with Ringer’s solution
(mm: NaCl 140, KHCO3 10, KH2PO4 0·4, K2HPO4 2·4,
CaCl2 1·2, MgCl2, 1·2) at 378C. For the entire experimental
period, animals were kept in a glass chamber where tem-
perature was maintained at 25–308C with the help of elec-
tric blankets and all perfusions were made at 378C. After
the initial wash, the loop was perfused for 15 min with
Ringer’s solution þ 2·0 mm-D-galactose and 3·700 kBq
D-[1-14C]galactose/ml (1184–1331 MBq/mmol; Amer-
sham International) through a tube connected to a peristal-
tic pump (Microperpex; LKB) at a flow rate of 2 ml/min.
At the end of this time, the intestine was flushed out
with saline (9 g NaCl/l) for 5 min. Both effluents were col-
lected separately and concentration of D-galactose
absorbed was calculated as the difference between the
amount of sugar in the solution before and after the per-
fusion period plus the substrate remaining in the final
washing solution. Radioactive samples were counted in a
Hisafe LKB liquid scintillator in a b counter (Wallac
1409/11; LSC, Pharmacia, Finland). Results were
expressed as mmol D-galactose/15 min per mm jejunum.
Laboratory studies and histological procedures
Serum levels of albumin, total protein, glucose, cholesterol,
bilirubin, alkaline phosphatase and aminotransferases
(aspartate aminotransferase and alanine aminotransferase)
were determined by routine laboratory methods using a
Hitachi 747 autoanalyser (Boerhringer-Mannheim, Lever
Russeu, Germany) at the beginning and at the end of the
experimental period. Conventional histological techniques
for optical microscopy were carried out using a light pro-
jection microscope (Micro Promar, Wetzlar, Germany).
Four or five segments of jejunum were evaluated in each
animal by two different observers. In addition, insulin
(Insik-5w; Sorin Biomedica, Stockholm, Sweden), IGF-I
(DSL-2900 Rat IGF-I Radioimmunoassay; Sorin Biomedica),
growth hormone (Rat GH assay with Amerlex-Me; Amer-
sham Biosciences, London, UK) (inter- and intra-assay CV
(%) for these assays were: insulin 3·2, IGF-I 5·4, growth
hormone 2·4), thyroid-stimulating hormone (Rat TSH
assay system with Amerlex-Me), triiodothyronine
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and thyroxine (Coat-A-Countw Total T3 DPC and
T4-CTRIA; CIS Bio International, San Francisco, CA,
USA) were assessed in the samples of blood taken at the
end of the N balance study.
Histological scoring of liver fibrosis
In liver sections stained with Masson’s Trichrome, semi-
quantitative assessment of fibrosis was performed blindly
by using a numerical scoring system based on the
number, length and thickness of fibrous septa, each one
scored from one to four points depending on their severity
(light projection microscope, £ 4 magnification; Micro
Promar Leitz Gmbh, Wetzlar, Germany) (Fujiwara et al.
1988). The minimal degree of fibrosis (score one point)
was ascribed to rats that showed a mild fibrosis in the peri-
portal space and around the central veins. Maximum length
of the septa (four points) was considered as greatest when
there was confluence between the portal tracts and around
the central veins. LC was scored as two or three when
intermediate lengths of septa were observed. On the other
hand, the number of collagen fibres was scored between
one and four as well. A score of four points was recorded
when the septa extended into the nodules surrounding one
or two hepatocytes ( £ 10 and £ 20 magnification). A score
of one to three points was given when fibre confluence or
penetration into nodules was less pronounced. Fibrous
septa width, calculated at £ 10 magnification, was
scored highest (four) when the degree of thickness
observed was maximum. For each preparation, four fields
were observed twice by two different and independent
observers. The arithmetical mean value of these scores
was taken as the final score.
Statistical analyses
Results were expressed as mean values with their standard
errors. Statistical analysis was done by one-way ANOVA
in combination with Tukey’s test. Any P value ,0·05
was considered to be statistically significant. Calculations
were performed with the SPSSW program, version 6.0
(SPSS Inc., Chicago, IL, USA).
Results
Table 1 shows that the procedure followed to induce liver
cirrhosis by CCl4 inhalation and Phen added to drinking
water was efficient. Besides the significantly lower
growth in CI rats, plasma transaminases, alkaline phospha-
tase, bilirubin and total cholesterol were markedly
increased in CI animals as compared with healthy untreated
rats. Glycaemia, proteinaemia, and urinary urea were sig-
nificantly reduced in CI rats. No changes were noted in
urinary creatinine or plasma non-esterified fatty acids.
Observation of the animals revealed no sign of ascitis in
any of the CI rats. In addition, the histological observation
of liver revealed the presence of micronodular or macromi-
cronodular cirrhosis. The histological score of fibrosis was
significantly lower (P,0·01) in CI þ IGF-I than in CI ani-
mals, with both groups showing higher scores than CO rats.
The electron microscopy of jejunum sections showed
microvilli enlargement. All present histological obser-
vations were similar to those previously reported by our
group in recent publications (Castilla et al. 1997a, 2000).
The effects of IGF-I on growth, relative organ and
muscles weights, and N balance variables in CI rats,
as well as those related to the effect of Phen and IGF-I
on CO rats are shown in Tables 2 and 3. No changes
were observed in organ or muscles weights, with the
exception of characteristic splenomegaly in both CI and
CI þ IGF-I rats and liver enlargement caused by Phen
administration (Table 2). No major differences in growth
were noted as a consequence of the different treatments.
N balance data showed that N retention, expressed per
kg BW, was significantly reduced in CI rats as compared
with either CO group (Table 3).
Administration of IGF-I to CI rats raised (P,0·05)
N retention to the value of healthy CO animals. A similar
pattern was observed with regard to digestibility (true
digestibility coefficient), true biological value and net
protein utilization. Administration of Phen to CO rats
caused a decrease in digestibility, biological value and
net protein utilization (Table 3). Administration of IGF-I
to control rats had almost no effect on any of the variables
assessed.
On the other hand, the effects of IGF-I on liver function
variables in CI rats, as well as those related to the effect of
Phen and IGF-I on CO rats are shown in Table 4. Adminis-
tration of IGF-I to CI rats significantly improved proteinae-
mia, albuminaemia, alkaline phosphatase, cholesterolaemia
and glycaemia. While the administration of IGF-I to CO rats
had no effect on liver function variables, a hypoglycaemic
effect was observed in CO rats treated with Phen.
The intestinal lipid absorption, as measured by total lipid
faeces content (Table 5) shows that the significant (P,0·01)
steatorrhoea observed in CI rats was not affected by IGF-I.
The markedly reduced in vivo intestinal capacity to
actively transport galactose by jejunum in CI rats (0·025
(SEM 0·001) mmol D-galatose/15 min per mm jejunum)
Table 1. Body weight and plasma liver function variables in rats at
the start of the experimental period†
(Mean values with their standard errors)
CO (n 40) CI (n 40)
Variable Mean SEM Mean SEM
Weight (g) 533·0 17·0 442·0*** 11·0
AST (IU/l) 549 52 2966*** 491
ALT (IU/l) 259 24 2735*** 494
Glucose (mmol/l) 2210 150 1170* 60
Total protein (g/l) 68·6 0·6 63·9* 1·8
Total cholesterol (mg/l) 816 39 1155*** 49
Alkaline
phosphatase (IU/ml)
310·0 43·0 701·0** 146·0
Bilirubin (mg/l) 4·4 0·4 121** 3·4
Urea (g/l) 39·6 1·7 28·2** 2·7
Creatinine (mg/l) 5·9 0·3 5·0 0·2
Non-esterified
fatty acids (mmol/l)
0·48 0·03 0·46 0·06
CO, control group; CI, ClC4-induced cirrhotic group; AST, asparate amino-
transferase; ALT, alanine aminotransferase.
Mean values were significantly different from those of the CO: *P,0·05,
**P,0·01, ***P,0·001.
† For details of procedures, see p. 930.
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was completely restored (P,0·001) to normal values by the
administration of IGF-I (0·035 (SEM 0·001) mmol D-gala-
tose/15 min per mm jejunum).
Finally, Table 6 shows that CI rats did not have reduced
plasma IGF-I levels, regardless of treatment, although
reduced growth and thyroid-related hormones levels were
observed in these animals.
Discussion
The results of the present study demonstrate that the
administration of 20mg IGF-I/kg BW had no effect on
liver function in healthy CO rats, supporting the fact that
hepatocytes are insensitive to their own IGF-I (Ross et al.
1996). The only effect of the peptide in these animals was
a dietary independent increase in true digestibility coeffi-
cient, an effect that could be related to an increase in
the intestinal transport of nutrients, as will be pointed
out later.
Since LC induction involved the ingestion of Phen
through drinking water, it seemed convenient to assess to
what extent the barbiturate itself might affect the nutri-
tional status of experimental animals. Our findings
showed that the effects of Phen were twofold. First, there
Table 2. Effect of treatment with insulin-like growth factor-I on body weight (g) and organ weights (g/kg body weight) in healthy control rats
and carbon tetrachloride-induced cirrhotic rats at the end of the 6 d N-balance period†
(Mean values with their standard errors)
CO (n 12) CO þ Phen (n 12)‡
CO þ IGF-I
(n 11)§ CI (n 10)
CI þ IGF-I
(n 11)§
Variable Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
Body weight 545 14 543 13 539 18 460*** 12 458*** 9
Liver 29·9 0·7 35·7*** 0·7 28·3 0·5 35·9 1·5 35·0 1·8
Spleen 1·5 0·1 1·5 0·1 1·5 0·1 3·2*** 0·4 3·0*** 0·3
Jejunum 5·9 0·2 5·4 0·3 6·1 0·3 6·1 0·2 6·5 0·3
Right kidney 2·4 0·1 2·3 0·1 2·4 0·1 2·7 0·1 2·7 0·1
Right testicle 3·6 0·1 3·6 0·1 3·4 0·1 3·5 0·1 3·6 0·1
Right femur 2·5 0·1 2·4 0·1 2·4 0·1 2·2 0·2 2·5 0·1
Gastrocnemius 5·3 0·1 5·5 0·2 5·4 0·2 5·9** 0·2 5·8* 0·1
Soleus 0·6 0·2 0·4 0·1 0·5 0·1 0·4 0·1 0·4 0·1
EDL 0·4 0·1 0·4 0·1 0·4 0·1 0·4 0·1 0·4 0·1
CO, control group; Phen, phenobarbital; IGF, insulin-like growth factor; CI, ClC4-induced cirrhotic group; EDL, extensor digitorum longus.
Mean values were significantly different from those of the CO: *P,0·05, **P,0·01, ***P,0·001.
† For details of procedures, see p. 930.
‡ Group received 400 mg Phen/l drinking water throughout the experimental period.
§ Groups received 20mg IGF-I/kg body weight per d subcutaneously for 14 d.
Table 3. Effect of treatment with insulin-like growth factor-I on nutritional variables in healthy control rats and carbon tetrachloride-induced
cirrhotic rats at the end of the 6 d N-balance period§
(Mean values with their standard errors)
CO (n 12)
CO þ
phen (n 12)k
CO þ IGF-I
(n 12){ CI (n 10)
CI þ IGF-I
(n 11){
Variable Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
Initial wt (g) 533 17 504 11 523 13 442*** 11 448*** 8
Final wt (g) 543 14 517 12 534 17 457*** 11 459*** 8
Weight gain (g/15 d) 9·2 6·4 12·7 2·6 22·8 0·7 14·9 1·7 11·3 1·8
Body wt (g) 540 14 509 11 535 16 448††† 11 453†† 8
Food intake (g/kg body wt) 276 11 293 8 264 11 283 8 311* 9
Water intake (ml/kg body wt) 439 17 460 21 381 30 481 35 415 39
BGI (initial wt/final wt) 1·02 0·01 1·02 0·01 0·99 0·01 1·03 0·01 1·02 0·04
N balance
N retained (g) 1·37 0·10 0·98* 0·06 1·40 0·10 0·85* 0·10 1·19 0·11
N retained (g/kg body wt) 2·5 0·2 1·9 0·1 2·6 0·2 1·8* 0·2 2·4 0·2
TDC (N absorbed £ 100/N ingested) 83·20 0·49 81·16** 0·41 84·80** 0·37 81·08** 0·39 82·30‡ 0·37
TBV (N retained/N absorbed) 41·20 2·31 31·05* 1·41 43·90 2·65 32·02* 3·95 36·37 3·47
NPU (TDC £ TBV/100) 34·35 2·04 25·21* 1·17 37·27 2·35 26·02* 3·26 29·91 2·84
CO, control group; Phen, phenobarbital; IGF, insulin-like growth factor; CI, ClC4-induced cirrhotic group; BGI, body growth index; TDC, true digestibility coefficient;
TBV, true biological value.
Mean values were significantly different from those of the CO: *P,0·05, **P,0·01, ***P,0·001.
Mean values were significantly different from those of the CO þ Phen: ††P,0·01, †††P,0·001
Mean value was significantly different from that of the CI: ‡P,0·05.
§ For details of procedures, see p. 930.
kGroup received 400 mg Phen/l drinking water throughout the experimental period.
{Groups received 20mg IGF-I/kg body weight per d subcutaneously for 14 d.
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was reduced digestibility and biological value of the
ingested protein: this could be associated with the depress-
ive action of Phen on the hypothalamic centres that control
appetite (Johnston & File, 1989), as well as with a
reduction in the general enzymatic capacity of the liver
(Dube et al. 1991; Kra¨henbuhl et al. 1991). Second,
there was a reduction of plasma glucose levels, which
may be related to the effect of Phen on the activity of hepa-
tic glycolytic or gluconeogenic enzymes.
The use of CCl4 inhalation with oral Phen is a well-vali-
dated method used by our group and by other workers to
induce the metabolic, haemodynamic and biochemical
alterations of LC in rats, resembling that caused by alcohol
in human subjects (Epstein, 1990; Plaa & Charbonneau,
1994). In the present study, a mixed micronodular pattern
of LC accompanied by mild portal hypertension, and
thereby mild signs of ascitis, was established. Most of
the biochemical and pathological criteria related to tissue
damage and cholestasis featuring LC were fulfilled in the
present study (Mullen & McCullough, 1989). The choice
of the dose of 20mg IGF-I/kg BW was based on previous
observations (Castilla et al. 1997b; Picardi et al. 1997)
suggesting that this is the optimal dose to counteract
many of the adverse effects caused by experimental LC
(Castilla et al. 1997a). In this, as well as previous studies,
plasma levels of IGF-I in CI rats were similar to those of
CO animals. Liver IGF-I synthesis diminished only when
the hepatic disease is advanced (Donaghy et al. 1995; Cas-
tilla et al. 2000). Higher doses of IGF-I have been used to
treat osteopaenia in postmenopausal women (Ebeling et al.
Table 4. Effect of treatment with insulin-like growth factor-I on plasma liver function variables in healthy control rats and carbon tetrachloride-
induced cirrhotic rats at the end of the 6 d N-balance period‡
(Mean values with their standard errors)
CO (n 12)
CO þ Phen
(n 12)§
CO þ IGF-I
(n 10)k CI (n 10)
CI þ IGF-I
(n 11)k
Variable Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
AST (IU/l) 368 33 362 39 375 2·0 797 146 843 189
ALT (IU/l) 194 13 215 19 214 14 401*** 44 411*** 59
Total protein (g/l) 64·9 0·8 67·1 0·9 65·4 0·9 61·7* 0·9 65·4 0·9
Albumin (g/l) 34·1 0·3 34·5 0·6 34·6 0·3 29·1*** 0·4 31·1***† 0·9
AP (IU/ml) 283 17 239 10 263 14 489*** 66 398*† 30
Bilirubin (mg/l) 4·0 0·8 4·8 0·4 3·1 0·4 9·9* 2·8 5·6 1·4
Cholesterol (mg/l) 826 41 894 46 743 48 1471* 320 1141 69
Glucose (mmol/l) 1920 70 1640** 80 1920 100 1610** 60 1900† 110
Non-esterified
fatty acids (mmol/l)
0·37 0·03 0·37 0·03 0·36 0·03 0·45 0·04 0·36 0·04
Urea (g/l) 33·4 1·3 32·6 1·1 36·2 1·2 29·0** 1·3 31·9 1·7
Creatinine (mg/l) 0·56 0·03 0·47** 0·01 0·54 0·01 0·43*** 0·01 0·44*** 0·02
Naþ (mmol/l) 140·9 0·6 139·1* 0·7 141·2 0·2 139·3 0·4 139·9 0·4
Kþ (mmol/l) 4·8 0·15 4·8 0·15 4·9 0·14 4·4 0·18 4·5 0·14
Cl2 (mmol/l) 107·6 0·6 105·4* 0·7 106·8 0·6 106·4 0·6 106·9 0·6
Ca2þ (mmol/l) 2·46 0·03 2·42 0·02 2·44 0·21 2·34 0·02‡ 2·39 0·02
CO, control group; Phen, Phenobarbital; IGF, insulin-like growth factor; CI, ClC4-induced cirrhotic group; AST, aspartate aminotransferase; ALT, alanine amino-
transterase; AP, alkaline phosphatase.
Mean values were significantly different from those of the CO: *P,0·05, **P,0·01, ***P,0·001.
Mean values were significantly different from those of the CI: †P,0·05.
‡ For details of procedures, see p. 930.
§ Group received 400 mg Phen/l drinking water throughout the experimental period.
kGroups received 20mg IGF-I/kg body weight per d subcutaneously for 14 d.
Table 5. Effect of treatment with insulin-like growth factor-I on faecal variables in healthy control rats and carbon tetrachloride-
induced cirrhotic rats at the end of the 6 d N-balance period†
(Mean values with their standard errors)
CO (n 12)
CO þ Phen
(n 12)‡
CO þ IGF-I
(n 12)§ CI (n 10)
CI þ IGF-I
(n 11)§
Variable Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
Faeces weight
Total (g/6 d) 22·1 0·9 22·7 1·2 19·7 1·1 20·5 0·6 20·2 0·7
g/kg body wt 40·5 1·7 44·4 1·6 35·6* 1·6 45·0 0·1 44·6 1·6
Fat in faeces
g/d 0·11 0·008 0·137 0·01 0·093 0·003 0·136 0·009 0·136 0·009
% 3·07 0·16 3·57 0·20 3·57 0·20 3·98** 0·27 4·04** 0·23
CO, control group; Phen, Phenobarbital; IGF, insulin-like growth factor; CI, ClC4-induced cirrhotic group.
Mean values were significantly different from those of the CO: *P,0·05, **P,0·01.
† For details of procedures, see p. 930.
‡ Groups received 400mg Phen/l drinking water throughout the experimental period.
§ Groups received 20mg IGF-I/kg body weight per d subcutaneously for 14 d.
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1993). Interestingly, although moderate LC does not affect
plasma IGF-I levels, it may have some influence on IGF-I-
binding proteins levels (Smith et al. 1995), and therefore
on IGF-I bioavailability. However, low IGF-I levels are
associated with adverse clinical outcomes in cirrhotic
patients (Donaghy et al. 2002), as the liver is the primary
source of circulating IGF-I. Measurement of IGF-I in the
tissues of the growth hormone receptor knockout model
(in which IGF-I mRNA expression is not reduced) will
be needed to confirm that the post-transcriptional steps of
IGF-I synthesis have been not affected (Lupu et al. 2001).
In human subjects, it is quite common to observe signs
of protein–energy malnutrition only in advanced stages
of LC, but not in moderate, compensated LC (Campillo
et al. 1992; Mu¨ller et al. 1992). As compared with CO ani-
mals, cirrhotic rats had no differences in food intake and
relative weights of bone, muscle, testicle and kidney.
This emphasizes the fact that a moderate, compensated
liver fibrosis was established in cirrhotic rats. Nevertheless,
these animals exhibited a state of malnutrition character-
ized by decreased weight gain, hypoglycaemia, hypoprotei-
naemia, especially hypoalbuminaemia, and reduced N
balance. In addition, total digestibility coefficient, total bio-
logical value and net protein utilization were reduced as
well. As mentioned earlier, advanced LC is usually associ-
ated with skeletal muscle wasting (McCullough & Tavill,
1991), with the urinary output of N-methylhistidine (an
indicator of myofibrillar protein breakdown) increased in
cases of LC (Marchesini et al. 1982; Zoli et al. 1982).
On the other hand, it has been reported that IGF-I may
increase synthesis (Russell-Jones et al. 1994) and reduce
breakdown of muscle proteins (Jacob et al. 1989). How-
ever, the degree of LC in the present study was not
severe enough to cause changes in either soleus, a red, oxi-
dative muscle with slow-twitch fibres, or in the extensor
digitorum longus, a white, glycolytic muscle with fast-
twitch fibres. The paradoxical increase of G weight, a
mixed muscle composed of both red and white fibres,
found in both CI and CI þ IGF-I rats agrees with pre-
viously reported results (Picardi et al. 1997) and correlates
with the reduced creatinuria. This finding may be related to
the special effect of LC on reducing adipose tissue in skel-
etal muscle (Hobler et al. 1998) or to a specific target
action of the peptide on this big postural muscle.
The most relevant effect of the administration of IGF-I
found in the present study was the significant improvement
in all the nutritional variables assessed, such as food intake,
plasma albumin, N balance, total digestibility coefficient,
true biological value and net protein utilization. All of
these measurements, reduced in CI rats, were partly or
completely matched to control values in CI þ IGF-I. In
addition, cholestasis, as judged by plasma alkaline phos-
phatase, bilirubin and cholesterol values, was significantly
improved in treated cirrhotic rats, but not to the point of
correcting the steatorrhoea associated with cirrhotic rats
(Salvioli et al. 1990; Merli et al. 1992). Several mechan-
isms may explain, at least partly, the beneficial effects of
IGF-I. First, as has been reported by Castilla et al.
(1997a), Holt et al. (1998) and Schalah et al. (1998),
IGF-I caused an outstanding improvement in liver function.
It has to be emphasized that fibrogenesis was reduced in CI
rats receiving the dose of IGF-I used in the present study in
accordance with previous findings (Muguerza et al. 1995;
Castilla et al. 1997a). Second, a reduced food intake
seems to play a role in the undernutrition observed in
cirrhotic subjects (Muller, 1998). Although this extreme
was not seen in our present study, the administration of
IGF-I to CI rats caused an increase in food intake that
might have contributed to improving the nutritional
status, in accordance with results from previous studies
(Picardi et al. 1997). It is accepted that the liver plays a
central role in controlling appetite through the regulation
of both glycaemia and aminoacidaemia (Felber & Galay,
1995). Moreover, a possible direct effect of IGF-I on the
hypothalamic centres that control the sensation of hunger
and satiety cannot be discarded. In any case, the increased
food intake observed in CI þ IGF rats was not associated
with hypoglycaemic conditions, since plasma glucose
levels were elevated in the treated animals. The low
plasma level of glucose in CI rats is related to the insulin
resistance, a well-documented characteristic of cirrhotic
subjects (Petrides & Defronzo, 1989). As a result, there
Table 6. Effect of treatment with insulin-like growth factor-I on plasma hormone levels in healthy control rats and carbon
tetrachloride-induced cirrhotic rats at the end of the 6 d N-balance period‡
(Mean values with their standard errors)
CO CO þ Phen§ CI CI þ IGF-Ik
Variable Mean SEM Mean SEM Mean SEM Mean SEM
IGF-I (ng/ml) 2577 62 3590** 221 3232** 260 2826 226
GH (ng/ml) 38·30 1·17 36·40** 1·49 33·63** 0·90 21·64†† 0·64
Insulin (mU/l) 41·92 2·46 40·44 4·56 45·33 3·45 37·48 3·82
TSH (ng/ml) 6·93 3·11 2·26 0·95 3·97 1·71 1·95* 1·22
T3 (nmol/l) 1·84 0·09 1·63 0·21 1·66 0·21 1·19* 0·16
T4 (nmol/l) 108·1 0·52 160·3*** 7·0 105·7†† 10·7 88·5†† 4·5
CO, control group; Phen, Phenobarbitali; IGF, insulin-like growth factor; CI, ClC4-induced cirrhotic group, GH, growth hormone; TSH,
thyroid-stimulating hormone; T3, triiodothyronine; T4, thyroxine.
Mean values were significantly different from those of the CO: *P,0·05, **P,0·01, ***P,0·001.
Mean values were significantly different from those of the CO-Phen: ††P,0·01.
* For details of procedures, see p. 930.
§ Group received 400 mg Phen/l drinking water throughout the experimental period.
kGroup received 20mg IGF-I/kg body weight per d subcutaneously for 14 d.
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is a reduced muscle glycogen synthesis and a shift to fatty
acid utilization and gluconeogenesis, at the expense of
muscular amino acids, arising from reduced muscle protein
synthesis or muscle protein increased breakdown (Menden-
hall et al. 1984).
Despite the increased food intake and N retention, no
body-weight gain was observed as a consequence of the
treatment. This is in agreement with the finding of other
workers (Picardi et al. 1997), and was not due to alterations
in body water or Na balance.
Unlike findings of our previous studies (Picardi et al.
1997), the N bioavailability was reduced in CI rats and
completely restored by the peptide. This difference is
most probably explained by the degree of LC, severe
enough in the study of Picardi et al. (1997) to significantly
affect the N metabolism and amino acid intestinal trans-
port. In more recent studies, we have shown that LC rats
exhibited reduced intestinal transport of leucine, proline,
glutamate and cysteine, accompanied by gut morphological
disturbances characterized by microvilli enlargement
(Pascual et al. 2000). Both functional and morphological
alterations were restored by administering IGF-I at the
same dose used in the present study. Therefore, the
improvement in the intestinal amino acid transport seems
to play a central role in the nutritional improvement
caused by IGF-I in CI rats.
With regard to the reduced thyroid-stimulating hormone,
thyroxine and triiodothyronine levels observed in both trea-
ted and untreated CI rats, it has been reported that there is
an inverse correlation between plasma levels of thyroid
hormones and of total cholesterol, LDL-cholesterol, hepa-
tic synthesis of apolipoprotein B-100 and bile excretion,
hepatic excretion of LDL (VLDL)-cholesterol and activity
of LDL receptors and hydroxymethylglutaryl-CoA
reductase (Potter, 1995). In addition, the decrease of triio-
dothyronine might be associated to a blunted thyronine
deiodinase type I activity, responsible for most of the
conversion of thyroxine into triiodothyronine. This
enzyme depends on the trace elements Zn and Se, and
bioavailability of trace elements is impaired in liver disease
(Scholmerich et al. 1987; Navarro-Alarcon & Lo´pez,
2000).
The beneficial effect on dietary N bioavailability in CI
rats caused by IGF-I treatment could be related to an
improvement in monosaccharide metabolism caused by
the peptide. Our present study showed that the in vivo
absorption of D-galactose in jejunal loops was markedly
decreased in CI rats and recovered to a large extent when
those animals were treated with IGF-I for 5 d. As men-
tioned earlier, CI rats exhibited a marked microvilli
enlargement that could alter the spatial insertion of the
Naþ–glucose transporter-1 within the microvilli lipid
layer, thereby impairing the affinity of the protein to
couple both Naþ and galactose (or glucose). This agrees
with our previously published work in which specific
Naþ–glucose transporter-1 antibodies were used to stain
the transporter in the microvili (Castilla et al. 1997b) and
may explain the modifications of both Km and Vmax
found in the present study. Since IGF-I is capable of restor-
ing microvilli structure, it seems feasible that, as a conse-
quence, the transporter insertion in the membrane returns
to its physiological position, allowing recovery of the phys-
iological capacity of the brush border to transport
monosaccharides.
In conclusion, the administration of 20mg human recom-
binant IGF-I/kg BW to moderately cirrhotic rats for 14 d
significantly improved N balance variables and restored
in vivo intestinal transport of sugars, while having no
effect on the steatorrhoea caused by the disease. These
results suggest that low doses of IGF-I may have beneficial
effects on the malnutrition associated with moderate LC.
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